Journal article
Interim Estimates of 2024-2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years - VISION and IVY Networks, September 2024-January 2025
MMWR. Morbidity and mortality weekly report, Vol.74(6), pp.73-82
02/27/2025
DOI: 10.15585/mmwr.mm7406a1
PMCID: PMC11867580
PMID: 40014628
Abstract
COVID-19 vaccination averted approximately 68,000 hospitalizations during the 2023-24 respiratory season. In June 2024, CDC and the Advisory Committee on Immunization Practices (ACIP) recommended that all persons aged ≥6 months receive a 2024-2025 COVID-19 vaccine, which targets Omicron JN.1 and JN.1-derived sublineages. Interim effectiveness of 2024-2025 COVID-19 vaccines was estimated against COVID-19-associated emergency department (ED) or urgent care (UC) visits during September 2024-January 2025 among adults aged ≥18 years in one CDC-funded vaccine effectiveness (VE) network, against COVID-19-associated hospitalization in immunocompetent adults aged ≥65 years in two networks, and against COVID-19-associated hospitalization among adults aged ≥65 years with immunocompromising conditions in one network. Among adults aged ≥18 years, VE against COVID-19-associated ED/UC visits was 33% (95% CI = 28%-38%) during the first 7-119 days after vaccination. Among immunocompetent adults aged ≥65 years from two CDC networks, VE estimates against COVID-19-associated hospitalization were 45% (95% CI = 36%-53%) and 46% (95% CI = 26%-60%) during the first 7-119 days after vaccination. Among adults aged ≥65 years with immunocompromising conditions in one network, VE was 40% (95% CI = 21%-54%) during the first 7-119 days after vaccination. These findings demonstrate that vaccination with a 2024-2025 COVID-19 vaccine dose provides additional protection against COVID-19-associated ED/UC encounters and hospitalizations compared with not receiving a 2024-2025 dose and support current CDC and ACIP recommendations that all persons aged ≥6 months receive a 2024-2025 COVID-19 vaccine dose.COVID-19 vaccination averted approximately 68,000 hospitalizations during the 2023-24 respiratory season. In June 2024, CDC and the Advisory Committee on Immunization Practices (ACIP) recommended that all persons aged ≥6 months receive a 2024-2025 COVID-19 vaccine, which targets Omicron JN.1 and JN.1-derived sublineages. Interim effectiveness of 2024-2025 COVID-19 vaccines was estimated against COVID-19-associated emergency department (ED) or urgent care (UC) visits during September 2024-January 2025 among adults aged ≥18 years in one CDC-funded vaccine effectiveness (VE) network, against COVID-19-associated hospitalization in immunocompetent adults aged ≥65 years in two networks, and against COVID-19-associated hospitalization among adults aged ≥65 years with immunocompromising conditions in one network. Among adults aged ≥18 years, VE against COVID-19-associated ED/UC visits was 33% (95% CI = 28%-38%) during the first 7-119 days after vaccination. Among immunocompetent adults aged ≥65 years from two CDC networks, VE estimates against COVID-19-associated hospitalization were 45% (95% CI = 36%-53%) and 46% (95% CI = 26%-60%) during the first 7-119 days after vaccination. Among adults aged ≥65 years with immunocompromising conditions in one network, VE was 40% (95% CI = 21%-54%) during the first 7-119 days after vaccination. These findings demonstrate that vaccination with a 2024-2025 COVID-19 vaccine dose provides additional protection against COVID-19-associated ED/UC encounters and hospitalizations compared with not receiving a 2024-2025 dose and support current CDC and ACIP recommendations that all persons aged ≥6 months receive a 2024-2025 COVID-19 vaccine dose.
Details
- Title: Subtitle
- Interim Estimates of 2024-2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years - VISION and IVY Networks, September 2024-January 2025
- Creators
- Ruth Link-GellesSean ChickeryAlexander WebberToan C OngElizabeth A K RowleyMalini B DeSilvaKristin DascombStephanie A IrvingNicola P KleinShaun J GrannisMichelle A BarronSarah E ReeseCharlene McEvoyTamara SheffieldAllison L NalewayOusseny ZerboColin RogersonWesley H SelfYuwei ZhuAdam S LauringEmily T MartinIthan D PeltanAdit A GindeNicholas M MohrKevin W GibbsDavid N HagerMatthew E PrekkerAmira MohamedNicholas JohnsonJay S SteingrubAkram KhanJamie R FelzerAbhijit DuggalJennifer G WilsonNida QadirChristopher MallowJennie H KwonCristie ColumbusIvana A VaughnBasmah SafdarJarrod M MosierEstelle S HarrisJames D ChappellNatasha HalasaCassandra JohnsonKarthik Natarajan - Columbia University Irving Medical CenterNathaniel M LewisSascha EllingtonEmily L ReevesJennifer DeCuirMeredith McMorrowClinton R PadenAmanda B PayneFatimah S DawoodDiya SurieCDC COVID-19 Vaccine Effectiveness Collaborators
- Resource Type
- Journal article
- Publication Details
- MMWR. Morbidity and mortality weekly report, Vol.74(6), pp.73-82
- DOI
- 10.15585/mmwr.mm7406a1
- PMID
- 40014628
- PMCID
- PMC11867580
- NLM abbreviation
- MMWR Morb Mortal Wkly Rep
- ISSN
- 1545-861X
- eISSN
- 1545-861X
- Publisher
- CENTERS DISEASE CONTROL & PREVENTION
- Language
- English
- Date published
- 02/27/2025
- Academic Unit
- Epidemiology; Emergency Medicine; Anesthesia; Injury Prevention Research Center
- Record Identifier
- 9984795369102771
Metrics
8 Record Views